Key facts
- Bond Biosciences’s last known valuation is $121.8M (Jan 2022).
- It has raised $17.1M across 2 recorded rounds; the latest was Early Stage VC ($5.9M) in Apr 2026.
- Notable investors include National Institutes of Health, BioGenerator Ventures, Collage Venture Partners, Emerald Bioventures, Transhuman Capital.
- Bond Biosciences has filed 4 Form Ds with the SEC since 2024, most recently Jan 2026 ($4.5M sold to 91 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Bond Biosciences
Funding rounds
2 roundsAbout Bond Biosciences
Developer of small molecule-based therapeutics designed to prevent and treat ion-related human diseases. The company offers polymer-based compounds, targeted ion-binding mechanisms, and oral drug candidates, enabling patients with ion-related conditions to manage disease progression and reduce complications.
- Sector
- Healthcare
- HQ
- Parkville, MO, United States
- Founded
- 2015
- Employees
- 3
- Website
- bond.bio/
- Ownership
- Privately Held (backing)
Bond Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bond Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bond Biosciences in its N-PORT filings yet. We sweep new filings monthly.